System and method for applying therapy during hyperpnea phase of periodic breathing using an implantable medical device

• US 7,454,250 B1
• Filed: 07/29/2005
• Issued: 11/18/2008
• Est. Priority Date: 04/21/2004
• Status: Active Grant

• Current Assignee: Pacesetter Incorporated (Abbott Laboratories)
• Original Assignee: Pacesetter Incorporated (Abbott Laboratories)
• Inventors: Benser, Michael, Park, Euljoon, Bjorling, Anders
• Primary Examiner(s): Evanisko; George R
• Assistant Examiner(s): HOLMES, REX R
• Application Number:
  US11/192,779
• Time in Patent Office: 1,208 Days
• Field of Search: 607/42, 600/484, 600/529, 600/532, 600/534, 600/53
• US Class Current: 607/42
• CPC Class Codes: A61N 1/3601 of respiratory organs
• CPC Class Codes: A61N 1/3611 Respiration control stimulating respiratory organs A61N1/3601

Abstract

Techniques are provided for treating periodic breathing, such as Cheyne-Stokes Respiration, using an implantable medical system. In one technique, diaphragmatic stimulation is delivered during a hyperpnea phase of periodic breathing via electrical stimulation of the phrenic nerves. Diaphragmatic stimulation is synchronized with intrinsic inspiration so as to increase the amplitude of diaphragmatic contraction during inspiration. This tends to decrease intrathoracic pressure leading to occlusion of the respiratory airway. Occlusion reduces actual ventilation during hyperpnea, thus reducing the cyclic blood chemistry imbalance that sustains periodic breathing so as to either mitigate periodic breathing or eliminate it completely. In another technique, respiration is instead inhibited during the hyperpnea phase of periodic breathing by blocking phrenic nerve signals to the extent necessary to reduce ventilation to terminate periodic breathing or at least mitigate its severity. Techniques are also described for controlling the type of therapy applied in response to periodic breathing.

Claims

1. A method for delivering therapy in response to periodic breathing within a patient using an implantable medical system, the method comprising:

detecting periods of hyperpnea during periodic breathing; and

occluding the patient'"'"'s upper airway to selectively inhibit respiration during detected periods of hyperpnea.

2. The method of claim 1 wherein respiration is inhibited during the periods of hyperpnea by an amount sufficient to mitigate periodic breathing.

3. The method of claim 1 wherein the respiration is inhibited in response to periods of hyperpnea occurring during Cheyne-Stokes Respiration.

4. The method of claim 1 wherein occluding the patient'"'"'s upper airway to inhibit respiration during hyperpnea comprises selectively blocking intrinsic nerve signals propagating along the hypoglossal nerve of the patient during the periods of hyperpnea.

5. The method of claim 1 further comprising determining whether frank apnea is occurring during the hypopnea periods of the periodic breathing and wherein respiration inhibition is performed during the periods of hyperpnea only if frank apnea is found to occur during the hypopnea periods.

6. The method of claim 1 further comprising determining volume of airflow during periodic breathing and occluding the patient'"'"'s upper airway to selectively inhibit respiration when the volume of airflow exceeds a threshold level.

7. The method of claim 1 further comprising monitoring duration of detected periods of hyperpnea and occluding the patient'"'"'s upper airway to selectively inhibit respiration when the duration of the detected hypernpea periods exceeds a threshold level.

8. The method of claim 3 further comprising determining if Cheyne-Stokes Respiration was terminated and selectively blocking intrinsic nerve signals propagating along the phrenic nerves of the patient during the periods of hyperpnea if Cheyne-Stokes Respiration was not terminated.

9. An implantable medical system for delivering therapy in response to periodic breathing within a patient, the system comprising:

a periodic breathing detection system operative to detect episodes of periodic breathing and to identify periods of hyperpnea therein; and

a nerve inhibitor operative to block intrinsic nerve signals propagating along a hypoglossal nerve of the patient to selectively inhibit respiration during the periods of hyperpnea.

10. The implantable medical system of claim 9 further comprising an implantable phrenic nerve inhibitor operative to block intrinsic nerve signals propagating along phrenic nerves of the patient during the periods of hyperpnea.

11. An implantable medical system for delivering therapy in response to periodic breathing within a patient, the system comprising:

means for detecting periods of hyperpnea during periodic breathing; and

means for occluding the patient'"'"'s upper airway to selectively inhibit respiration during detected periods of hyperpnea.

12. The implantable medical system of claim 11 wherein the respiration is inhibited in response to periods of hyperpnea occurring during Cheyne-Stokes Respiration.

13. The implantable medical system of claim 11 wherein the means for occluding the patient'"'"'s upper airway to inhibit respiration during hyperpnea comprises means for selectively blocking intrinsic nerve signals propagating along the hypoglossal nerve of the patient during the periods of hyperpnea.

14. The implantable medical system of claim 11 further comprising means for determining volume of airflow during periodic breathing and wherein the means for occluding the patient'"'"'s upper airway to selectively inhibit respiration comprises means for occluding the patient'"'"'s upper airway when the volume of airflow exceeds a threshold level.

15. The implantable medical system of claim 11 further comprising means for monitoring duration of detected periods of hyperpnea and wherein the means for occluding the patient'"'"'s upper airway to selectively inhibit respiration comprises means for occluding the patient'"'"'s upper airway when the duration of the detected hyperpnea period exceeds a threshold level.